43 completed, 5 recruiting, 5 unknown, 1 active not recruiting. 56 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 56 | Completed 43, Recruiting 5, Unknown 5, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 4, Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow Gels: new trials by email Literature Review of Gels trials Research Report on Gels
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2/3 Efficacy and Safety of PP405 in Adult Males PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia | Phase 2 / Phase 3 | Recruiting | Pelage Pharmaceuticals, Inc. | 600 | 2026-09-21 | 2026-10-28 |
| Topical Calcipotriol Versus Photodynamic Therapy in the Treatment of Oral Leukoplakia Calcipotriol 0.005% gel, ALA mediated PDT - Oral Leukoplakia | Phase 2 / Phase 3 | Active not recruiting | Alexandria University | 30 | 2025-07-16 | 2026-06-22 |
| A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) EscharEx (EX-03), Placebo (Gel vehicle) - Venous Leg Ulcer (VLU) | Phase 3 | Recruiting | MediWound Ltd | 216 | 2025-06-01 | 2026-10-09 |
| Tissue Repair Gel in Venous Leg Ulcers in AU/US TR987 0.1% gel + Standard of Care, Standard of care - Venous Leg Ulcer, Venous Ulcer | Phase 3 | Recruiting | TR Therapeutics | 312 | 2025-04-01 | 2025-04-02 |
| Tissue Repair Gel in Venous Leg Ulcers (US) TR987 0.1% gel + Standard of Care, Standard of care - Venous Leg Ulcer, Venous Ulcer | Phase 3 | Recruiting | TR Therapeutics | 312 | 2025-01-28 | 2026-02-12 |
| A Study to Assess Efficacy and Safety of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Patients With Acne Vulgaris (GEDACNE-1) N-Acetyl-GED-0507-34-Levo 5% gel, N-Acetyl-GED-0507-34-Levo corresponding vehicle - Acne Vulgaris | Phase 3 | Completed | PPM Services S.A. | 407 | 2024-11-19 | 2026-09-15 |
| Pregabalin Gel in Reducing Post-operative Tooth Sensitivity Surgery Caused by Bleaching With 35% Hydrogen Peroxide pregabalin gel, gel with 5% potassium nitrate and 2% sodium fluoride, Placebo gel - Tooth Bleaching, Sensitivity, Tooth | Phase 3 | Unknown | Universidade Federal do Para | 75 | 2024-01-05 | 2023-12-22 |
| A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy SNP-ACTH (1-39) Gel, Rituximab - Primary Membranous Nephropathy | Phase 3 | Recruiting | Cerium Pharmaceuticals, Inc. | 148 | 2023-03-13 | 2026-06-25 |
| Lidocaine for Pessary Check Pain Reduction Lidocaine Hcl 2% Jelly, Placebo Jelly - Pelvic Organ Prolapse, Stress Urinary Incontinence | Phase 3 | Completed | University of South Florida | 66 | 2022-09-08 | 2023-12-14 |
| Biofreeze and the Effect on Knee Osteoarthritis Biofreeze 4 % Topical Gel, Biofreeze placebo gel - Knee Osteoarthritis | Phase 2 / Phase 3 | Completed | Memorial University of Newfoundland | 70 | 2020-11-01 | 2024-12-04 |
| Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1% Adapalene 0.1% Gel, Differin 0.1% Topical Gel, Placebo - Acne Vulgaris | Phase 3 | Withdrawn | Aurobindo Pharma Ltd | 2020-07-01 | 2020-06-26 | |
| Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study Diclofenac diethylamine 2.32% gel, Diclofenac diethylamine 1.16% gel, Placebo - Pain | Phase 3 | Completed | GlaxoSmithKline | 313 | 2019-10-24 | 2022-04-12 |
| Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd), ACZONE® (dapsone) gel, 7.5% (Allergan, INC.), Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd) - Acne Vulgaris | Phase 3 | Completed | Torrent Pharmaceuticals Limited | 1150 | 2019-07-11 | 2020-04-02 |
| Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo - Acne Vulgaris | Phase 3 | Completed | Aleor Dermaceuticals Limited | 755 | 2018-09-17 | 2019-04-26 |
| Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris Clindamycin 1% Gel, Placebo - Acne Vulgaris | Phase 3 | Completed | Akorn, Inc. | 1125 | 2018-04-27 | 2020-10-05 |
| Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis Diclofenac Sodium Gel, Solaraze 3% Topical Gel, Placebo - Actinic Keratoses | Phase 3 | Completed | Encube Ethicals Pvt. Ltd. | 655 | 2018-01-12 | 2019-02-01 |
| Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne Adapalene 0.3% / BPO 2.5% gel - Acne Vulgaris | Phase 3 | Completed | Galderma R&D | 50 | 2017-02-02 | 2021-02-18 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts CLS006 (Furosemide) Topical Gel, Vehicle Topical Gel - Cutaneous Common Warts | Phase 3 | Completed | Maruho Co., Ltd. | 484 | 2017-01-01 | 2023-09-14 |
| Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations Brimonidine 0.33% gel - Capillary Malformations | Phase 3 | Terminated | The Hospital for Sick Children | 6 | 2016-06-01 | 2019-04-16 |
| Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan) - Acne Vulgaris | Phase 3 | Completed | Seegpharm S.A. | 2361 | 2016-02-01 | 2016-12-20 |
Showing 20 of 56. Sign in to see all of them.
Acne Vulgaris (16) · Keratosis, Actinic (4) · Rosacea (4) · Varicose Ulcer (3) · Infections (2) · Kidney Diseases (2) · Mycoses (2) · Osteoarthritis, Knee (2) · Tinea Pedis (2) · Wounds and Injuries (2) · Agnosia (1) · Alopecia (1) · Ankle Injuries (1) · Capillary Malformations, Congenital, 1 (1) · Cicatrix (1)
Galderma R&D (9) · GlaxoSmithKline (3) · Peplin (3) · Cadence Pharmaceuticals (2) · Mantecorp Industria Quimica e Farmaceutica Ltd. (2) · MediWound Ltd (2) · Merz North America, Inc. (2) · TR Therapeutics (2) · Actavis Inc. (1) · Akorn, Inc. (1) · Aleor Dermaceuticals Limited (1) · Alexandria University (1) · Amirhossein Farahmand (1) · Assistance Publique - Hôpitaux de Paris (1) · Aurobindo Pharma Ltd (1)
United States (36) · Canada (10) · Belize (5) · Germany (5) · Italy (4) · Australia (3) · Brazil (3) · France (3) · Japan (3) · Poland (3) · Spain (3) · China (2) · India (2) · Israel (2) · Puerto Rico (2)
Michael Graeber, M.D. (2) · Michael Graeber, MD (2) · Adele Sparavigna, Doctor (1) · Adis Tasanarong, MD (1) · Alexa Kimball, MD, MPH (1) · Araba A Jackson, MD (1) · Caryn Thompson, MBA (1) · Catherine J Hardalo, MD (1) · Christina Weng (1) · Diane Thiboutot, MD (1) · Dr Dharmesh Domadia, M.D (1) · Eglal M Moussa, PhD oral medicine (1) · Elena Pope, MD (1) · Fernando Fervenza, MD, PhD (1)
PMID 22417254, PMID 19746769, PMID 19845233, PMID 22395584, PMID 26945741, PMID 27172434, PMID 27531752, PMID 28236223, PMID 28686775, PMID 28686776, PMID 31251543, PMID 32785881, PMID 34397196, PMID 35667420, PMID 36566202, PMID 37715999, PMID 40024965
2023 (1), R01AG037603 (1)